Elviucitabine

Medical Advocates
Elvucitabine (L-Fd4C)

Main Page

New and Noteworthy
Journal Abstracts, Papers, and Commentaries
Conference Reports, Abstracts, and Posters

Main New/Noteworthy

Home Page

Last Update: March 11, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

February 2010

POSTER
Elvucitabine vs Lamivudine with Tenofovir and Efavirenz in ART-naīve HIV-1-infected Patients:
96-week Final Results
E DeJesus, D Saple, J Morales-Ramirez, et al
17th CROI
PDF Poster Abstract

Journal Papers, Abstracts, and Commentaries

Pharmacokinetics

The Multiple-Dose Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor,
when Administered over 21 Days with Lopinavir/Ritonavir in HIV-1 Subjects
Colucci P, Pottage JC, Robison H, et al Antimicrob Agents Chemother. 2008 Nov 17.

The Effect of a Single Dose of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, when Administered
in Healthy Volunteers
Colucci P, Pottage JC, Robison H, et al Antimicrob Agents Chemother. 2008 Nov 17.

Conference Citations

17th Conference on Retroviruses and Opportunistic Infections

POSTER
Elvucitabine vs Lamivudine with Tenofovir and Efavirenz in ART-naīve HIV-1-infected Patients:
96-week Final Results
E DeJesus, D Saple, J Morales-Ramirez, et al
PDF Poster Abstract

Main New/Noteworthy

Home Page

Elvucitabine